This is probably why we won’t see a cap raise. I think prior to the new proteomics data it may have been more likely, however with the multiple new indications possible and with a 9 month preclin/clin parallel program for the FDA and a MS P2 trial in lieu, I think ANP MD will have taken the partnership route to fund these different pipelines. M
We shall see soon, fingers crossed.
This is probably why we won’t see a cap raise. I think prior to...
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
